A
Arijit Nag
Researcher at Medical College and Hospital, Kolkata
Publications - 31
Citations - 144
Arijit Nag is an academic researcher from Medical College and Hospital, Kolkata. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 5, co-authored 26 publications receiving 114 citations.
Papers
More filters
Journal ArticleDOI
Development of a colour Doppler ultrasound scoring system in patients of Takayasu’s arteritis and its correlation with clinical activity score (ITAS 2010)
TL;DR: CDUS imaging could be a cost-effective, non-invasive and reliable substitute for angiogram, especially for follow-up in Takayasu's arteritis patients and would be a supplementary tool to clinical scoring and the ITAS.
Journal ArticleDOI
Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients.
Jyoti Shaw,Ayan Chakraborty,Arijit Nag,Arnab Chattopadyay,Anjan Kr. Dasgupta,Maitreyee Bhattacharyya +5 more
TL;DR: To investigate the cause and effects of intracellular iron overload in lymphocytes of thalassemia major patients, a large number of patients with this condition have suffered from iron overload.
Journal ArticleDOI
Ultrasonography as a useful modality for documenting sacroiliitis in radiographically negative inflammatory back pain: a comparative evaluation with MRI
TL;DR: USG can be a cost-effective and non-inferior modality compared with MRI in documenting sacroiliitis in early SpA and correlate the findings with that of MRI.
Journal ArticleDOI
Acute kidney injury and dermonecrosis after Loxosceles reclusa envenomation.
Arijit Nag,J Datta,Anamika Das,A K Agarwal,Debanjali Sinha,Sumantro Mondal,Tony Ete,Ayan Chakraborty,S Ghosh +8 more
TL;DR: A case of AKI, hemolysis and a “gravitational” pattern of ulceration following the bite of the brown recluse spider (Loxosceles spp) is reported.
Journal ArticleDOI
Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience.
Arijit Nag,Vivek S. Radhakrishnan,Jeevan Kumar,Saurabh Bhave,Deepak Mishra,Reena Nair,Mammen Chandy +6 more
TL;DR: Thalidomide is a safe and effective strategy at reducing or abrogating transfusion requirement in patients with EB thalassemia and this approach requires further testing in systematic clinical trials.